AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21710355 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C (then-test questions included)
Number of subjects: 949
Study 21710355 — intervention group
Group type: COMPARATOR
Intervention: Group B (transition questions included)
Number of subjects: 949
Study 21710355 — intervention group
Group type: COMPARATOR
Intervention: Group A (post-test questions only)
Number of subjects: 949
Study 20462897 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to stable ST-segment reperfusion (TSTR)
Number of subjects: 137
Study 20462897 — intervention group
Group type: EXPERIMENTAL
Intervention: TSTR cutoff value of 136.5 minutes
Number of subjects: 137
Study 20462897 — intervention group
Group type: EXPERIMENTAL
Intervention: Killip class > or = 2
Number of subjects: 137
Study 20462897 — intervention group
Group type: EXPERIMENTAL
Intervention: Final TIMI flow grade III
Number of subjects: 137
Study 18558645 — intervention group
Group type: EXPERIMENTAL
Intervention: IPT‐MOMS (n=26)
Number of subjects: 47
Study 18558645 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (n=21)
Number of subjects: 47
Study 16858935 — intervention group
Group type: EXPERIMENTAL
Intervention: Roselle flower tea (RFT) administered at 4,000 mg in 480 ml of hot distilled water
Number of subjects: 0
Study 11824237 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic therapy (thermal, mechanical, and injection procedures)
Number of subjects: 0
Study 9541732 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% chloramphenicol and 0.5% pale sulfonated shale oil
Number of subjects: 91
Study 9541732 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% chloramphenicol
Number of subjects: 91
Study 9541732 — intervention group
Group type: COMPARATOR
Intervention: Alcoholic vehicle
Number of subjects: 91
Study 7804294 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral physostigmine
Number of subjects: 36
Study 7804294 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine
Number of subjects: 36
Study 7804294 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 3134556 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxamniquine 60 mg/kg
Number of subjects: 296
Study 3134556 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxamniquine 40 mg/kg
Number of subjects: 296
Study 3134556 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxamniquine 20 mg/kg
Number of subjects: 296
Study 3134556 — intervention group
Group type: COMPARATOR
Intervention: Oxamniquine (all doses)
Number of subjects: 296
Study 30928925 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy meal replacement diet (average ≈810 kcal/day)
Number of subjects: 90
Study 30928925 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise programme for 12 weeks
Number of subjects: 90
Study 30928925 — intervention group
Group type: COMPARATOR
Intervention: Guideline-directed clinical care with lifestyle coaching
Number of subjects: 90
Study 28607070 — intervention group
Group type: EXPERIMENTAL
Intervention: Decentralized communication networks
Number of subjects: 0
Study 28607070 — intervention group
Group type: COMPARATOR
Intervention: Centralized networks
Number of subjects: 0
Study 26468074 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural fentanyl 25 μg
Number of subjects: 135
Study 26468074 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural meperidine 25 mg
Number of subjects: 135
Study 26468074 — intervention group
Group type: COMPARATOR
Intervention: Epidural clonidine 2 μg/kg
Number of subjects: 135
Study 24529670 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine infusion (0.1 mg/kg/hour)
Number of subjects: 50
Study 24529670 — intervention group
Group type: COMPARATOR
Intervention: Control group (saline infusion)
Number of subjects: 50
Study 24529670 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine infusion
Number of subjects: 50
Study 24529670 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 21377295 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol 400 μg
Number of subjects: 80
Study 21377295 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 19694865 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention toolkit including admission form with geriatric cues, facsimile to the primary care provider, interdisciplinary worksheet, pharmacist-physician collaborative medication reconciliation, predischarge planning appointments.
Number of subjects: 185
Study 19694865 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention toolkit
Number of subjects: 185
Study 17507345 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-glycemic load diet (40% carbohydrate and 35% fat)
Number of subjects: 73
Study 17507345 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet (55% carbohydrate and 20% fat)
Number of subjects: 73
Study 15254060 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (600 mg/d to 1,800 mg/d)
Number of subjects: 121
Study 15254060 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 15254060 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 121
Study 11229465 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular glucocorticoid treatment (120 mg of methylprednisolone acetate)
Number of subjects: 40
Study 9751468 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg methylprednisolone in mepivacaine 0.25%
Number of subjects: 20
Study 9751468 — intervention group
Group type: COMPARATOR
Intervention: Mepivacaine (placebo)
Number of subjects: 20
Study 7908257 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg SL 84.0418
Number of subjects: 0
Study 7908257 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg SL 84.0418
Number of subjects: 0
Study 7908257 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg SL 84.0418
Number of subjects: 0
Study 7908257 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg glipizide
Number of subjects: 0
Study 7908257 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3391876 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin acistrate (EA) 400 mg tid
Number of subjects: 2
Study 3391876 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin base (EB) 500 mg tid
Number of subjects: 2
Study 3391876 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin acistrate (EA) 500 mg tid
Number of subjects: 2
Study 29910837 — intervention group
Group type: EXPERIMENTAL
Intervention: LMWF‐5A
Number of subjects: 168
Study 29910837 — intervention group
Group type: COMPARATOR
Intervention: Saline (historical control)
Number of subjects: 168
Study 27248436 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention based on social learning theory and the Health Belief Model (HBM)
Number of subjects: 3570
Study 27248436 — intervention group
Group type: COMPARATOR
Intervention: Wait list control
Number of subjects: 3570
Study 25624132 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 μg/d of nasal fluticasone propionate
Number of subjects: 0
Study 25624132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23826101 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin 75 mg/m2 and docetaxel 75 mg/m2 (Epi/Doc)
Number of subjects: 30
Study 21628653 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01(E)
Number of subjects: 860
Study 21628653 — intervention group
Group type: COMPARATOR
Intervention: Control vaccine
Number of subjects: 860
Study 19433683 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed 500 mg/m² plus carboplatin AUC = 5 on day 1
Number of subjects: 436
Study 19433683 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine 1,000 mg/m² on days 1 and 8 plus carboplatin AUC = 5 on day 1
Number of subjects: 436
Study 16969059 — intervention group
Group type: EXPERIMENTAL
Intervention: Primaquine 30 mg once daily for 7 days (group A, n = 71)
Number of subjects: 141
Study 16969059 — intervention group
Group type: EXPERIMENTAL
Intervention: Elubaquine 25 mg once daily for 7 days (group B, n = 70)
Number of subjects: 141
Study 15590356 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalaprilat infusion (0.06 mg/kg/hr) during CPB
Number of subjects: 30
Study 15590356 — intervention group
Group type: COMPARATOR
Intervention: Control group (dopamine infusion only)
Number of subjects: 30
Study 11704167 — intervention group
Group type: EXPERIMENTAL
Intervention: 49-day cycle (42 active pills)
Number of subjects: 90
Study 11704167 — intervention group
Group type: COMPARATOR
Intervention: 28-day cycle (21 active pills)
Number of subjects: 90
Study 8961507 — intervention group
Group type: EXPERIMENTAL
Intervention: PFP-2 vaccine
Number of subjects: 64
Study 8961507 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 2145238 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone
Number of subjects: 10
Study 478062 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterosan-hydrocortison ointment
Number of subjects: 3
Study 478062 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterosan ointment
Number of subjects: 3
Study 478062 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterosan cream
Number of subjects: 3
Study 478062 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of chlorquinaldol
Number of subjects: 3
Study 31811627 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-session empathetic communication skills training
Number of subjects: 82
Study 31811627 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 82
Study 30699438 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time fMRI-guided neurofeedback training to enhance connectivity between the ventrolateral prefrontal cortex (vlPFC) and the amygdala
Number of subjects: 26
Study 30699438 — intervention group
Group type: COMPARATOR
Intervention: Sham control pathway
Number of subjects: 26
Study 27704590 — intervention group
Group type: EXPERIMENTAL
Intervention: Incredible Years® Toddler Parenting Programme
Number of subjects: 89
Study 25705958 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymorphone Hydrochloride (OH)
Number of subjects: 24
Study 25705958 — intervention group
Group type: EXPERIMENTAL
Intervention: Propoxyphene/Acetaminophen (PA)
Number of subjects: 24
Study 25705958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 24581076 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-led, synchronous groups using live chat
Number of subjects: 102
Study 22182419 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral treatments for adolescent marijuana abuse or dependence
Number of subjects: 165
Study 22182419 — intervention group
Group type: EXPERIMENTAL
Intervention: Delay discounting task for $100 and $1,000 of hypothetical money and marijuana
Number of subjects: 165
Study 22182419 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic variables (socioeconomic status, race)
Number of subjects: 165
Study 20835896 — intervention group
Group type: EXPERIMENTAL
Intervention: LAGB at optimal volume
Number of subjects: 17
Study 20835896 — intervention group
Group type: COMPARATOR
Intervention: LAGB empty
Number of subjects: 17
Study 17948223 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery followed by uracil-tegafur 360 mg/m²/day for 16 months
Number of subjects: 190
Study 17948223 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 190
Study 15606304 — intervention group
Group type: EXPERIMENTAL
Intervention: mFISH analysis of plutonium-exposed subjects
Number of subjects: 0
Study 11867823 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (AZM) 250 mg/day
Number of subjects: 60
Study 11867823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 10438349 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1 immunogen 10 U
Number of subjects: 10
Study 10438349 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1 immunogen 2.5 U
Number of subjects: 10
Study 10438349 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1 immunogen
Number of subjects: 10
Study 8885737 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical assist device (SutureMate)
Number of subjects: 476
Study 8885737 — intervention group
Group type: COMPARATOR
Intervention: Usual fashion (control arm)
Number of subjects: 476
Study 1948598 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 per cent bupivacaine plus epinephrine 1 to 200,000
Number of subjects: 30
Study 1948598 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 per cent bupivacaine
Number of subjects: 30
Study 1948598 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution
Number of subjects: 30
Study 1948598 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 30
Study 6222086 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 13-cis-retinoic acid at 0.1 mg/kg/day
Number of subjects: 20
Study 6222086 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 13-cis-retinoic acid at 0.5 mg/kg/day
Number of subjects: 20
Study 6222086 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 13-cis-retinoic acid at 1.0 mg/kg/day
Number of subjects: 20
Study 6222086 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of oral 13-cis-retinoic acid
Number of subjects: 20
Study 6222086 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical response to treatment
Number of subjects: 20
Study 31111409 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrronium tosylate (2.4%) applied once daily
Number of subjects: 550
Study 30541586 — intervention group
Group type: EXPERIMENTAL
Intervention: Real electroacupuncture (EA)
Number of subjects: 100
Study 30541586 — intervention group
Group type: COMPARATOR
Intervention: Sham electroacupuncture (placebo)
Number of subjects: 100
Study 26914224 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate 0.15 mg/kg
Number of subjects: 130
Study 26914224 — intervention group
Group type: COMPARATOR
Intervention: Propofol 1.5 mg/kg
Number of subjects: 130
Study 26914224 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate 0.15 mg/kg with hydrocortisone
Number of subjects: 130
Study 23661634 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 36
Study 23661634 — intervention group
Group type: COMPARATOR
Intervention: L-dopa
Number of subjects: 36
Study 23661634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 22249601 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasound with perflutren contrast agent
Number of subjects: 13
Study 22249601 — intervention group
Group type: EXPERIMENTAL
Intervention: Postcontrast ultrasound
Number of subjects: 13
Study 19346662 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 241
Study 19346662 — intervention group
Group type: COMPARATOR
Intervention: ACEI
Number of subjects: 241
Study 17595007 — intervention group
Group type: EXPERIMENTAL
Intervention: Rumination (writing about the aggressive video for 20 min) combined with minor frustration
Number of subjects: 60
Study 17595007 — intervention group
Group type: COMPARATOR
Intervention: Minor frustration
Number of subjects: 60
Study 17595007 — intervention group
Group type: COMPARATOR
Intervention: No rumination (irrelevant task for 20 min)
Number of subjects: 60
Study 15196302 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 mg/kg intravenous LY293558
Number of subjects: 45
Study 15196302 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg subcutaneous sumatriptan
Number of subjects: 45
Study 15196302 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 14578014 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (FLU) 1 mg twice a day for 8 days
Number of subjects: 50
Study 14578014 — intervention group
Group type: COMPARATOR
Intervention: Oxazepam tapering (from 120 mg)
Number of subjects: 50
Study 14578014 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 50
Study 14578014 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (FLU)
Number of subjects: 50
Study 9835002 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic compression device
Number of subjects: 1017
Study 9835002 — intervention group
Group type: COMPARATOR
Intervention: Clamp compression technique
Number of subjects: 1017
Study 9892226 — intervention group
Group type: EXPERIMENTAL
Intervention: Exendin 9-39 (500 pmol x kg(-1) x min(-1))
Number of subjects: 9
Study 9892226 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 9
Study 2499464 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine (bolus doses of 5.3 to 15.9 mg)
Number of subjects: 0
Study 2499464 — intervention group
Group type: COMPARATOR
Intervention: Theophylline (58.3 +/- 3.3 mumol l‐1 plasma)
Number of subjects: 0
Study 2499464 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole (10 mg)
Number of subjects: 0
Study 2499464 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol, Atropine, Naloxone, Cromolyn Sodium
Number of subjects: 0
Study 2499464 — intervention group
Group type: COMPARATOR
Intervention: Hyperventilation
Number of subjects: 0
Study 842760 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein‐calorie supplementation program
Number of subjects: 0
Study 842760 — intervention group
Group type: COMPARATOR
Intervention: Vitamin and mineral supplement with one‐third of the calories
Number of subjects: 0
Study 30926369 — intervention group
Group type: EXPERIMENTAL
Intervention: M1095 (240 mg)
Number of subjects: 44
Study 30926369 — intervention group
Group type: EXPERIMENTAL
Intervention: M1095 (30, 60, 120, or 240 mg)
Number of subjects: 44
Study 30926369 — intervention group
Group type: EXPERIMENTAL
Intervention: M1095
Number of subjects: 44
Study 30926369 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 27845200 — intervention group
Group type: COMPARATOR
Intervention: High-dose KME (2g/d)
Number of subjects: 67
Study 27845200 — intervention group
Group type: COMPARATOR
Intervention: KME groups (low-dose and high-dose)
Number of subjects: 67
Study 26870788 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid 600 mg
Number of subjects: 38
Study 26870788 — intervention group
Group type: COMPARATOR
Intervention: Linezolid 300 mg
Number of subjects: 38
Study 26870788 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid (both doses)
Number of subjects: 38
Study 23446898 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% price discounts on F&Vs
Number of subjects: 199
Study 23446898 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% price discounts plus nutrition education
Number of subjects: 199
Study 23446898 — intervention group
Group type: COMPARATOR
Intervention: Nutrition education alone
Number of subjects: 199
Study 23446898 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 199
Study 22273030 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative assessment of experiences in the trial
Number of subjects: 0
Study 22273030 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivations for participation
Number of subjects: 0
Study 22273030 — intervention group
Group type: EXPERIMENTAL
Intervention: Fears associated with trial procedures
Number of subjects: 0
Study 22273030 — intervention group
Group type: EXPERIMENTAL
Intervention: Conducting qualitative research
Number of subjects: 0
Study 19262457 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional hemofiltration (CUF)
Number of subjects: 24
Study 19262457 — intervention group
Group type: COMPARATOR
Intervention: Metilprednisolone (steroids)
Number of subjects: 24
Study 16376296 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral workshop
Number of subjects: 85
Study 16376296 — intervention group
Group type: COMPARATOR
Intervention: Assessment‐only waitlist group
Number of subjects: 85
Study 15272899 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone 0.75 mg/kg on alternate days, plus vitamin D 600-1200 units/day and a calcium-enriched diet
Number of subjects: 66
Study 15272899 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 66
Study 11283143 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron plus metopimazine
Number of subjects: 221
Study 11283143 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron plus metopimazine plus prednisolone
Number of subjects: 221
Study 9242341 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-1 receptor antagonist (IL-1ra) 100 mg bolus followed by 2 mg/kg per hour intravenously for 72 hours (n = 20)
Number of subjects: 37
Study 9242341 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 17)
Number of subjects: 37
Study 8494702 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy including alkylating agents (n = 14)
Number of subjects: 26
Study 8494702 — intervention group
Group type: EXPERIMENTAL
Intervention: Oophorectomy (n = 12)
Number of subjects: 26
Study 8494702 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 79)
Number of subjects: 26
Study 3568065 — intervention group
Group type: EXPERIMENTAL
Intervention: Alclometasone dipropionate 0.05%
Number of subjects: 34
Study 3568065 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone 1.0%
Number of subjects: 34
Study 31484697 — intervention group
Group type: EXPERIMENTAL
Intervention: Angioplasty/stenting
Number of subjects: 213
Study 31484697 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-smokers
Number of subjects: 213
Study 31484697 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing lesion length
Number of subjects: 213
Study 31484697 — intervention group
Group type: COMPARATOR
Intervention: FDA-approved indication for stenting
Number of subjects: 213
Study 29724228 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonic and Phasic Alertness Training (TAPAT)
Number of subjects: 120
Study 29724228 — intervention group
Group type: COMPARATOR
Intervention: Active control training condition (computer games)
Number of subjects: 120
Study 27099137 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (5 mg)
Number of subjects: 11
Study 27099137 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 11
Study 24732867 — intervention group
Group type: EXPERIMENTAL
Intervention: Prucalopride 2 mg (n=98)
Number of subjects: 280
Study 24732867 — intervention group
Group type: EXPERIMENTAL
Intervention: Prucalopride 4 mg (n=70)
Number of subjects: 280
Study 24732867 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=112)
Number of subjects: 280